Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: Current perspectives

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Teixeira, P C ^a,b   Cutler, P ^a   Vuilleumier, N ^b,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 AUTOANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN; EPLERENONE; GELATINASE B; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ACUTE CORONARY SYNDROME; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HEMODIALYSIS; HUMAN; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; IMMUNOLOGY; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; AUTOANTIBODIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; IMMUNOGLOBULIN G;

EID: 84871362653     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/868251     Document Type: Article

References (52)

1. Packard R. R. S., Libby P., Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry 2008 54 1 24 38 2-s2.0-38749112555 10.1373/clinchem.2007.097360 (Pubitemid 351182593)
2. Blasi C., The autoimmune origin of atherosclerosis. Atherosclerosis 2008 201 17 32
3. Skaggs B. J., Hahn B. H., McMahon M., Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nature Reviews Rheumatology 2012 8 4 214 223 10.1038/nrrheum.2012.14
4. Zeller C. B., Appenzeller S., Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Current Cardiology Reviews 2008 4 2 116 122 2-s2.0-48249096012 10.2174/ 157340308784245775
5. Kaplan M. J., Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheumatic Disease Clinics of North America 2010 36 2 405 426 2-s2.0-77953250991 10.1016/j.rdc.2010.02.002
6. Roux-Lombard P., Pagano S., Montecucco F., Satta N., Vuilleumier N., Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clinical Reviews in Allergy and Immunology 2010 1 14 2-s2.0-78650427495 10.1007/s12016-010-8233-z
7. Rye K. A., Bursill C. A., Lambert G., Tabet F., Barter P. J., The metabolism and anti-atherogenic properties of HDL. Journal of lipid research 2009 50 S195 S200 2-s2.0-66349137054 10.1194/jlr.R800034-JLR200
8. Gordon S. M., Hofmann S., Askew D. S., Davidson W. S., High density lipoprotein: it's not just about lipid transport anymore. Trends in Endocrinology and Metabolism 2011 22 1 9 15 2-s2.0-78650519284 10.1016/j.tem.2010.10.001
9. Besler C., Lüscher T. F., Landmesser U., Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine 2012 4 4 251 268 10.1002/emmm.201200224
10. Dinu A. R., Merrill J. T., Shen C., Antonov I. V., Myones B. L., Lahita R. G., Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998 7 5 355 360 2-s2.0-0031817855 10.1191/096120398678920262 (Pubitemid 28347016)
11. Abe H., Tsuboi N., Suzuki S., Sakuraba H., Takanashi H., Tahara K., Tonozuka N., Hayashi T., Umeda M., Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosusr. Journal of Rheumatology 2001 28 5 990 995 2-s2.0-0035002670 (Pubitemid 32422578)
12. Delgado Alves J., Kumar S., Isenberg D. A., Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2003 42 7 893 899 2-s2.0-0041569770 10.1093/rheumatology/keg248 (Pubitemid 37220940)
13. Delgado Alves J., Ames P. R. J., Donohue S., Stanyer L., Noorouz-Zadeh J., Ravirajan C., Isenberg D. A., Antibodies to high-density lipoprotein and β 2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis and Rheumatism 2002 46 10 2686 2694 2-s2.0-0036822305 10.1002/art.10542 (Pubitemid 36118933)
14. Batuca J. R., Ames P. R. J., Isenberg D. A., Delgado Alves J., Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Annals of the New York Academy of Sciences 2007 1108 137 146 2-s2.0-34948862784 10.1196/annals.1422.016 (Pubitemid 47528727)
15. Ames P. R. J., Matsuura E., Batuca J. R., Ciampa A., Lopez L. L., Ferrara F., Iannaccone L., Delgado Alves J., High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 2010 19 6 711 716 2-s2.0-77951215754 10.1177/0961203309357765
16. Van Lenten B. J., Hama S. Y., De Beer F. C., Stafforini D. M., McIntyre T. M., Prescott S. M., La Du B. N., Fogelman A. M., Navab M., Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. Journal of Clinical Investigation 1995 96 6 2758 2767 2-s2.0-0028859490
17. Vuilleumier N., Bas S., Pagano S., Montecucco F., Guerne P. A., Finckh A., Lovis C., Mach F., Hochstrasser D., Roux-Lombard P., Gabay C., Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis and Rheumatism 2010 62 9 2640 2650 2-s2.0-77956386145 10.1002/art.27546
18. Loftus I. M., Naylor A. R., Goodall S., Crowther M., Jones L., Bell P. R. F., Thompson M. M., Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000 31 1 40 47 2-s2.0-0033982563 (Pubitemid 30035750)
19. Anselmi M., Garbin U., Agostoni P., Fusaro M., Pasini A. F., Nava C., Keta D., Turri M., Zardini P., Vassanelli C., Lo Cascio V., Cominacini L., Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis 2006 185 1 114 120 2-s2.0-30944435863 10.1016/j.atherosclerosis. 2005.05.020 (Pubitemid 43117557)
20. Vuilleumier N., Bratt J., Alizadeh R., Jogestrand T., Hafström I., Frostegård J., Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scandinavian Journal of Rheumatology 2010 39 6 447 453 2-s2.0-78649696099 10.3109/03009741003742755
21. Finckh A., Courvoisier D. S., Pagano S., Bas S., Chevallier-Ruggeri P., Hochstrasser D., Roux-Lombard P., Gabay C., Vuilleumier N., Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores ? Arthritis Care & Research 2012 64 6 817 825 10.1002/acr.21631
22. Vuilleumier N., Reber G., James R., Burger D., De Moerloose P., Dayer J. M., Roux-Lombard P., Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. Journal of Autoimmunity 2004 23 4 353 360 2-s2.0-9644262468 10.1016/j.jaut.2004.08.003 (Pubitemid 39574810)
23. Urieli-Shoval S., Linke R. P., Matzner Y., Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Current Opinion in Hematology 2000 7 1 64 69 2-s2.0-0033988643 10.1097/00062752-200001000-00012 (Pubitemid 30007690)
24. Malle E., Steinmetz A., Raynes J. G., Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993 102 2 131 146 2-s2.0-0027424029 (Pubitemid 23283948)
25. Vuilleumier N., Charbonney E., Fontao L., Alvarez M., Turck N., Sanchez J. C., Burkhard P. R., Mensi N., Righini M., Reber G., James R., Mach F., Chevrolet J. C., Dayer J. M., Frostegard J., Roux-Lombard P., Anti-(apolipoprotein A-I) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clinical Science 2008 115 1-2 25 33 2-s2.0-46449088745 10.1042/CS20070325 (Pubitemid 351930790)
26. Vuilleumier N., Rossier M. F., Pagano S., Python M., Charbonney E., Nkoulou R., James R., Reber G., MacH F., Roux-Lombard P., Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. European Heart Journal 2010 31 7 815 823 2-s2.0-77950489726 10.1093/eurheartj/ehq055
27. Fox K., Ford I., Steg P. G., Tendera M., Robertson M., Ferrari R., Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. The Lancet 2008 372 9641 817 821 2-s2.0-50649089781 10.1016/S0140-6736(08)61171-X
28. Kannel W. B., Kannel C., Paffenbarger R. S., Cupples A., Heart rate and cardiovascular mortality: the Framingham study. American Heart Journal 1987 113 6 1489 1494 2-s2.0-0023223146 (Pubitemid 17092823)
29. Diaz A., Bourassa M. G., Guertin M. C., Tardif J. C., Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. European Heart Journal 2005 26 10 967 974 2-s2.0-18844368814 10.1093/eurheartj/ehi190 (Pubitemid 40695027)
30. Pagano S., Satta N., Werling D., Offord V., de Moerloose P., Charbonney E., Hochstrasser D., Roux-Lombard P., Vuilleumier N., Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. Journal of Internal Medicine 2012 272 4 344 357
31. Vuilleumier N., Pagano S., Lalhou K., Poncet A., Charbonney E., Norman G. L., Mach F., Roux-Lombard P., Head-to-head comparison of auto-antibodies for cardiovascular outcome prediction after myocardial infarction: a prospective study. Journal of Clinical and Experimental Cardiology. In press 10.4172/2155-9880.1000169
32. Murphy T. P., Dhangana R., Pencina M. J., Zafar A. M., D'Agostino R. B., Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. Atherosclerosis 2011 216 2 452 457 2-s2.0-79957999651 10.1016/j.atherosclerosis.2011.02.020
33. Keller P. F., Pagano S., Roux-Lombard P., Sigaud P., Rutschmann O. T., Mach F., Hochstrasser D D., Vuilleumier N., Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. Journal of Internal Medicine 2012 271 5 451 462 10.1111/j.1365-2796.2011.02479.x
34. Reichlin T., Hochholzer W., Bassetti S., Steuer S., Stelzig C., Hartwiger S., Biedert S., Schaub N., Buerge C., Potocki M., Noveanu M., Breidthardt T., Twerenbold R., Winkler K., Bingisser R., Mueller C., Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. New England Journal of Medicine 2009 361 9 858 867 2-s2.0-69349099937 10.1056/NEJMoa0900428
35. Montecucco F., Vuilleumier N., Pagano S., Lenglet S., Bertolotto M., Braunersreuther V., Pelli G., Kovari E., Pane B., Spinella G., Pende A., Palombo D., Dallegri F., MacH F., Roux-Lombard P., Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. European Heart Journal 2011 32 4 412 421 2-s2.0-79951839869 10.1093/eurheartj/ ehq521
36. Schwartz S. M., Galis Z. S., Rosenfeld M. E., Falk E., Plaque rupture in humans and mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 4 705 713 2-s2.0-34247201438 10.1161/01.ATV.0000261709.34878.20 (Pubitemid 46606695)
37. Libby P., Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. Journal of Lipid Research 2009 50 S352 357 2-s2.0-66349137052 10.1194/jlr.R800099-JLR200
38. Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003 42 5 1050 1065 2-s2.0-0242441465 10.1161/01.HYP.0000102971. 85504.7c (Pubitemid 37413751)
39. Stenvinkel P., Carrero J. J., Axelsson J., Lindholm B., Heimbürger O., Massy Z., Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clinical Journal of the American Society of Nephrology 2008 3 2 505 521 2-s2.0-42549131781 10.2215/CJN.03670807
40. Hauser A. B., Stinghen A. E. M., Kato S., Bucharles S., Aita C., Yuzawa Y., Pecoits-Filho R., Characteristics and causes of immune dysfunction related to uremia and dialysis. Peritoneal Dialysis International 2008 28 supplement 3 S183 S187 2-s2.0-48849098927
41. Carrero J. J., Hua X., Stenvinkel P., Qureshi A. R., Heimbürger O., Bárány P., Lindholm B., Frostegrd J., Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrology Dialysis Transplantation 2009 24 11 3454 3460 2-s2.0-73949131809 10.1093/ndt/gfp309
42. Pawlak K., Pawlak D., Mysliwiec M., Oxidative stress influences CC-chemokine levels in hemodialyzed patients. Nephron Physiology 2004 96 4 p105 p112 2-s2.0-2342639671 10.1159/000077381 (Pubitemid 38586154)
43. Pruijm M., Schmidtko J., Aho A., Pagano S., Roux-Lombard P., Teta D., Burnier M., Vuilleumier N., High prevalence of anti-Apolipoprotein A-1 autoantibodies in maintenance haemodialysis and associations with dialysis vintage. Therapeutic Apheresis and Dialysis. In press 10.1111/j.1744-9987.2012. 01102.x
44. Ohtake T., Ishioka K., Honda K., Oka M., Maesato K., Mano T., Ikee R., Moriya H., Hidaka S., Kobayashi S., Impact of coronary artery calcification in hemodialysis patients: risk factors and associations with prognosis. Hemodialysis International 2010 14 2 218 225 2-s2.0-77956416281 10.1111/j.1542-4758.2009.00423.x
45. Vaziri N. D., Navab M., Fogelman A. M., HDL metabolism and activity in chronic kidney disease. Nature Reviews Nephrology 2010 6 5 287 296 2-s2.0-77951877661 10.1038/nrneph.2010.36
46. Satta N., Dunoyer-Geindre S., Reber G., Fish R. J., Boehlen F., Kruithof E. K. O., De Moerloose P., The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007 109 4 1507 1514 2-s2.0-33846899419 10.1182/blood-2005-03-024463 (Pubitemid 46239583)
47. Satta N., Kruithof E. K. O., Fickentscher C., Dunoyer-Geindre S., Boehlen F., Reber G., Burger D., De Moerloose P., Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 2011 117 20 5523 5531 2-s2.0-79956312573 10.1182/blood-2010- 11-316158
48. Yokota S. I., Minota S., Fujii N., Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. International Immunology 2006 18 4 573 580 2-s2.0-33645223685 10.1093/intimm/dxh399
49. Rossier M. F., Pagano S., Python M., Maturana A. D., James R. W., Mach F., Roux-Lombard P., Vuilleumier N., Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels. General Endocrinology 2012 153 3 1269 1278 10.1210/en.2011-1835
50. Srivastava R., Yu S., Parks B. W., Black L. L., Kabarowski J. H., Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis and Rheumatism 2011 63 1 201 211 2-s2.0-78650772175 10.1002/art.27764
51. Khot U. N., Khot M. B., Bajzer C. T., Sapp S. K., Ohman E. M., Brener S. J., Ellis S. G., Lincoff A. M., Topol E. J., Prevalence of conventional risk factors in patients with coronary heart disease. Journal of the American Medical Association 2003 290 7 898 904 2-s2.0-0042697063 10.1001/jama.290.7.898 (Pubitemid 37430461)
52. Nussinovitch U., Shoenfeld Y., Intravenous immunoglobulin-indications and mechanisms in cardiovascular diseases. Autoimmunity Reviews 2008 7 6 445 452 2-s2.0-51749096897 10.1016/j.autrev.2008.04.001